Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | XPO1 | O14980 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | LYN | P07948 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL397746 | 0.99 | DDR1 (0.48) | DDR1CSF1RHIF1AXPO1RAF1 | |
| SCHEMBL12552677 | 0.87 | ALDH1A1 (0.55) | DDR1CSF1RHIF1ARAF1BRAF | |
| SCHEMBL25534421 | 0.87 | DDR1 (0.51) | DDR1CSF1RHIF1ARAF1BRAF | |
| SCHEMBL3312553 | 0.87 | ALDH1A1 (0.49) | DDR1CSF1RHIF1ARAF1BRAF | |
| SCHEMBL15131534 | 0.87 | CHEK1 (0.46) | DDR1CHEK1TEKFFAR4NPC1 | |
| SCHEMBL1420719 | 0.86 | ALDH1A1 (0.54) | DDR1CSF1RHIF1ARAF1BRAF | |
| SCHEMBL4727601 | 0.86 | HPGD (0.53) | XPO1ADRB1CYP3A4TSHRFFAR4 | |
| Trifluoroacetic Acid SCHEMBL15123461 | 0.86 | FFAR4 (0.43) | DDR1CSF1RHIF1AXPO1RAF1 | |
| SCHEMBL4726103 | 0.85 | HPGD (0.51) | XPO1ADRB1CYP3A4TSHRFFAR4 | |
| SCHEMBL1135082 | 0.85 | CHRM4 (0.50) | DDR1XPO1RAF1BRAFFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473278-B2 | Imidazole derivative expressing FLT3 inhibitory activity, and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2025-11-18 | — | — | US | disclosed |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-19 | — | — | US | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| US-20220315573-A1 | Novel Imidazole Derivative Expressing FLT3 Inhibitory Activity, and Use Thereof | Industry-University Cooperation Foundation Hangyang University Erica Campus (KR) | 2022-10-06 | — | — | US | disclosed |
| EP-3412670-B1 | PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2022-03-09 | — | — | EP | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-109071543-B | Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use | 三进制药株式会社 | 2021-07-16 | — | — | CN | disclosed |
| CN-108699038-B | Spirocyclic heptane salicylamides and related compounds as Rock inhibitors | 百时美施贵宝公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008051757-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051757-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007092531-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-08-16 | — | — | WO | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315573-A1 | Novel Imidazole Derivative Expressing FLT3 Inhibitory Activity, and Use Thereof | FLT3, FLI1, MCL1 | DDR1 1951/4885CSF1R 6/4885HIF1A 3219/4885 |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | DDR1 1402/4885CSF1R 3080/4885HIF1A 2226/4885 |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | DDR1 629/4885CSF1R 89/4885HIF1A 2395/4885 |
| US-12473278-B2 | Imidazole derivative expressing FLT3 inhibitory activity, and use thereof | FLT3, FLI1, MCL1 | DDR1 1781/4885CSF1R 8/4885HIF1A 3144/4885 |
| US-20240308994-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | CSF1R, CSF3R, IL15RA | DDR1 2984/4885CSF1R 1/4885HIF1A 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.